The Supply of Leronlimab will naturally be limited, especially for the short term. Does an EUA usually allow doctors to decide when to use the drug?

Possibly the FDA will issue a kind of limited EUA, approving the use of Leronlimab for now, to be restricted to certain patients per specific criteria for example co-morbidity categories and s/c symptoms, for patients who are most likely to be saved from death. Just until manufacturing can catch up with demand.